WallStreetZenWallStreetZen

NYSEMKT: NAVB
Navidea Biopharmaceuticals Inc Stock Ownership - Who owns Navidea Biopharmaceuticals?

Insider buying vs selling

Have Navidea Biopharmaceuticals Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Joshua M. WilsonDirector2022-11-2930,000$0.00
$30.00Buy

1 of 1

NAVB insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when NAVB insiders and whales buy or sell their stock.

NAVB Shareholders

What type of owners hold Navidea Biopharmaceuticals Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Mark Nordlicht93.17%30,152,862$9.95MInsider
Platinummontaur Life Sciences LLC42.86%13,872,531$4.58MInsider
Michael M. Goldberg18.29%5,921,023$1.95MInsider
David C. Bupp9.56%3,093,130$1.02MInsider
Reuven Avital9.50%3,074,379$1.01MInsider
Vanguard Group Inc2.06%667,740$220.35kInstitution
Frederick O. Cope1.83%593,689$195.92kInsider
Eric K. Rowinsky1.06%341,446$112.68kInsider
Great Point Partners LLC1.04%335,000$110.55kInsider
Brent L. Larson0.99%320,318$105.70kInsider

1 of 3

NAVB vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
NAVB2.62%97.38%Net Buying
IMNN0.00%100.00%Net Buying
HILS0.72%62.07%Net Buying
PSTV7.81%66.53%Net BuyingNet Selling
OBSV15.55%7.29%Net BuyingNet Buying

Navidea Biopharmaceuticals Stock Ownership FAQ

Who owns Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSEMKT: NAVB) is owned by 5.05% institutional shareholders, 187.40% Navidea Biopharmaceuticals insiders, and 0.00% retail investors. Mark Nordlicht is the largest individual Navidea Biopharmaceuticals shareholder, owning 30.15M shares representing 93.17% of the company. Mark Nordlicht's Navidea Biopharmaceuticals shares are currently valued at $9.14M.

If you're new to stock investing, here's how to buy Navidea Biopharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.